Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00256854 · ClinicalTrials.gov registry record · Phase 3
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
NCT00256854 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 135 participants.
The verdict
NCT00256854, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
Study Summary
This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.
Interventions
- DRUG Ropinirole IR 1 mg
- DRUG Ropinirole IR 2 mg
- DRUG Ropinirole IR 1 mg Placebo
- DRUG Ropinirole IR 2 mg Placebo
- DRUG Ropinirole CR 2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2005-11-14 |
| Est. Completion | 2006-09-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00256854
The ClinicalTrials.gov registry entry for NCT00256854 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ropinirole IR 1 mg is the first listed.
NCT00256854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00256854 about?
NCT00256854 is a clinical study titled "Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)". This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.
What is the current status of trial NCT00256854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2005-11-14. Estimated completion is 2006-09-21.
What interventions are being tested in trial NCT00256854?
The interventions under investigation include: Ropinirole IR 1 mg (DRUG), Ropinirole IR 2 mg (DRUG), Ropinirole IR 1 mg Placebo (DRUG), Ropinirole IR 2 mg Placebo (DRUG), Ropinirole CR 2 mg (DRUG).
Who is sponsoring clinical trial NCT00256854?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.